Targeted Treatment for Recurrent or Progressive Lung Cancer
Phase II Study of Sorafenib in Patients with Recurrent or Progressive Stage IV Non-Small-Cell Lung Cancer (NCI-05-C-0049). See the protocol summary at http://cancer.gov/clinicaltrials/NCI-05-C-0049. This trial was originally featured in the October 18, 2005, issue of the NCI Cancer Bulletin.
Why This Trial Is Important
In this clinical trial, researchers are testing a new drug called sorafenib to see if it can cause tumors to shrink or disappear in patients with metastatic non-small-cell lung cancer (NSCLC) that has recurred or progressed after previous treatment with chemotherapy. Sorafenib inhibits a protein called Raf kinase, which helps promote cell proliferation. Blocking Raf kinase activity may halt the spread of cancer cells.
Sorafenib also inhibits two other proteins named vascular endothelial growth factor receptors 2 and 3 (VEGFR2 and VEGFR3), which help tumors form new blood vessels (a process called angiogenesis). By blocking VEGFR2 and VEGFR3 activity, sorafenib may help cut off the blood supply to tumors and cause them to die.
"Sorafenib is a molecularly targeted oral medication with both antiproliferative and antiangiogenic properties," said Dr. Gutierrez. "It has shown some promising results against NSCLC in an earlier phase I study, and it appears to be well tolerated. Most of the toxicity that we have seen has been mild and easy to control."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.